Kennedy Capital Management LLC Has $128,000 Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

Kennedy Capital Management LLC grew its position in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 22.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 33,976 shares of the company’s stock after purchasing an additional 6,297 shares during the period. Kennedy Capital Management LLC’s holdings in COMPASS Pathways were worth $128,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Franklin Resources Inc. raised its stake in shares of COMPASS Pathways by 4.4% during the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after acquiring an additional 12,599 shares during the last quarter. Brown University increased its holdings in COMPASS Pathways by 194.6% in the fourth quarter. Brown University now owns 214,200 shares of the company’s stock valued at $810,000 after purchasing an additional 141,500 shares during the period. Renaissance Technologies LLC raised its position in COMPASS Pathways by 161.3% during the 4th quarter. Renaissance Technologies LLC now owns 212,700 shares of the company’s stock worth $804,000 after purchasing an additional 131,300 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in COMPASS Pathways by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock worth $661,000 after buying an additional 26,787 shares during the period. Finally, BIT Capital GmbH bought a new stake in shares of COMPASS Pathways in the 4th quarter valued at about $437,000. 46.19% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CMPS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a research note on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 target price for the company. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, COMPASS Pathways currently has an average rating of “Buy” and an average price target of $20.20.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $3.02 on Wednesday. COMPASS Pathways plc has a 12 month low of $2.49 and a 12 month high of $9.63. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $279.87 million, a price-to-earnings ratio of -1.37 and a beta of 2.34. The firm has a fifty day simple moving average of $3.50 and a two-hundred day simple moving average of $4.32.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.